Estonia
Tuberculosis profile
| High HIV burden | High MDR-TB burden |
Population  2012 1.3 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.036 (0.036–0.036) 2.8 (2.8–2.8)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.47 (0.35–0.59)
Prevalence  (includes HIV+TB) 0.38 (0.16–0.68) 29 (13–52)
Incidence  (includes HIV+TB) 0.3 (0.26–0.34) 23 (20–26)
Incidence (HIV+TB only) 0.039 (0.034–0.044) 3 (2.7–3.4)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 105 (45) Relapse 25 (45)
Smear-negative 109 (47) Treatment after failure 10 (18)
Smear-unknown / not done 1 (<1) Treatment after default 9 (16)
Extrapulmonary 19 (8) Other 12 (21)
Other 0 (0)      
Total new 234   Total retreatment 56  
           
Other (history unknown) 0        
Total new and relapse 259   Total cases notified 290  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 3.4 2.0 1.7
Age < 15 0 1 1
Laboratories 2012
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 7.7
Drug susceptibility testing (per 5 million population) 7.7
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 59   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 77  
Retreatment 31  
TB/HIV 2012 Number (%)
TB patients with known HIV status 271 (93)
HIV-positive TB patients 45 (17)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 28 (62)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 20 (14–26) 50 (35–65)
MDR-TB cases among notified pulmonary
TB cases
42 (31–56) 28 (20–36)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 193 (100%) 46 (82%) 239
Laboratory-confirmed MDR-TB cases 38 23 62
Patients started on MDR-TB treatment     54
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data